Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson's Disease and Movement Disorders - Presentations Highlight New Data on Diagnostic Accuracy and Novel Biom

Alterity Therapeutics Rare

Disease Natural History Study to be Featured at the

International Congress of Parkinson's Disease and Movement Disorders

- Presentations Highlight New Data

on Diagnostic Accuracy and Novel Biomarkers of Disease

Severity in Multiple System Atrophy -

MELBOURNE, AUSTRALIA AND SAN FRANCISCO,

USA - 22 August 2023: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"),

a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that poster

presentations from its bioMUSE natural history study of Multiple System Atrophy (MSA) will be delivered at the International Congress

of Parkinson's Disease and Movement Disorders taking place August 27 - 31, 2023 in Copenhagen, Denmark.

Biomarkers of progression in Multiple System

Atrophy (bioMUSE) is a natural history study that aims to track the progression of individuals with MSA, a parkinsonian disorder

without approved therapy. The study is being conducted in collaboration with Vanderbilt University Medical Center in the U.S. under

the direction of Daniel Claassen, M.D., M.S., Professor of Neurology and Principal Investigator. Natural history studies are

important for characterizing disease progression in selected patient populations. The study has provided rich data for optimizing

the design of Alterity's randomized ATH434-201 Phase 2 clinical trial and enrolled approximately 20 individuals with

clinically probable or clinically established MSA. BioMUSE continues to provide vital information on early stage MSA patients,

informs the selection of biomarkers suitable to evaluate target engagement and preliminary efficacy, and delivers clinical data to

characterize disease progression in a patient population that mirrors those currently enrolling in the Phase 2 clinical trial.

About Multiple System Atrophy

Multiple System Atrophy (MSA) is a

rare, neurodegenerative disease characterized by failure of the autonomic nervous system and impaired movement. The symptoms reflect the

progressive loss of function and death of different types of nerve cells in the brain and spinal cord. It is a rapidly progressive disease

and causes profound disability. MSA is a Parkinsonian disorder characterized by a variable combination of slowed movement and/or rigidity,

autonomic instability that affects involuntary functions such as blood pressure maintenance and bladder control, and impaired balance

and/or coordination that predisposes to falls. A pathological hallmark of MSA is the accumulation of the protein -synuclein within

glia, the support cells of the central nervous system, and neuron loss in multiple brain regions. MSA affects approximately 15,000 individuals

in the U.S., and while some of the symptoms of MSA can be treated with medications, currently there are no drugs that are able to slow

disease progression and there is no cure.1

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical

stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company's

lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical

trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat

the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For

further information please visit the Company's web site at www.alteritytherapeutics.com.

Authorisation & Additional information

This announcement was authorized by David Stamler, CEO of Alterity

Therapeutics Limited.

Investor and Media Contacts:

Forward Looking Statements

This press release contains "forward-looking

statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934.

The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes,"

"anticipates," "believes," "could," "may," "evidences" and "estimates," and

other similar expressions, but these words are not the exclusive means of identifying such statements.

Important factors that could

cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled

"Risk Factors" in the Company's filings with the SEC, including its most recent Annual Report on Form 20-F as well as

reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including,

but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but

not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including,

but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory

approval, production and marketing of the Company's drug components, including, but not limited to, ATH434, the ability of the Company

to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's

drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining

patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company's

patent rights and the uncertainty of the Company freedom to operate.

Any forward-looking statement

made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is

made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time

to time, whether as a result of new information, future developments or otherwise.